Objectives: Previous studies conducted on the human CFTR gene have reported that exon 10 and its flanking introns are present in multiple copies in the human genome. The c.1392+6insC and c.1392+12G>A variations are found in all duplicated sequences, but are not authentic mutations in CFTR. To understand the recent evolution of this part of the genome, the comparison of this CFTR region in humans and in 8 different primates had been performed. Methods: DNA extraction, sequencing and BLAST analyses were performed on the studied species.
WS21.6 A novel 5 alternative CFTR mRNA isoform may be a cause of CFTR dysfunction in a patient with nasal polyposis A. Hinzpeter 1,2 , A. de Becdelièvre 1,3 , E. Bieth 4 , C. Gameiro 3 , F. Brémont 5 , N. Martin 1 , B. Costes 1,2 , C. Costa 1,3 , A. Aissat 1,2 , M. Goossens 1,2,3 , P. Fanen 1,2 , E. Girodon 1,3 . 1 INSERM U955, GH Henri Mondor, Creteil, France; 2 Universite Paris-Est, Creteil, France; 3 GH Henri Mondor, APHP, Genetics, Creteil, France; 4 Purpan Hospital, Genetics, Toulouse, France; 5 Purpan Hospital, Pediatric CF Center, Pediatric Pulmonology, Toulouse, France Objectives: Cystic Fibrosis (CF) may be revealed by nasal polyposis (NP) starting early in life. We performed CFTR DNA and messenger RNA (mRNA) analyses in the family of a 12 y-old boy presenting with isolated NP and a normal sweat test. Methods: Routine DNA analysis only showed the heterozygous c.2551C>T, p.Arg851* (R851X) mutation in the child and the father. Qualitative mRNA analysis showed partial exon 15 skipping, associated with c.2551C>T. Quantitative mRNA analysis exhibited a significant increase of about 30% of total CFTR mRNA in the patient and the mother, which was the result of the heterozygous c.-2954G>A variant in the distant promoter region, as demonstrated by in vitro luciferase assays. Search for a 5 alternative abnormal transcript by 5 RACE analysis revealed the presence of a novel transcript, in which the canonical exon 1 was replaced by an alternative exon that we called 1a-L (1a-Long). Conclusion: This case report could represent the first description of a CFTR pathology associated with an increase of CFTR mRNA amount and the presence of a novel and probably non functional transcript.
WS21.7 Identification and characterization of two novel mutations in conserved sequences tags (CSTs) of CFTR gene
R. Tomaiuolo 1 , M. Scorza 1 , A. Elce 1 , S. Giordano 1 , G. Castaldo 1 . 1 Università di Napoli Federico II, Napoli, Italy
Objectives: We studied the intronic regions of CFTR searching for novel factors involved in the regulation of CFTR expression. About 7% of CF patients do not bear mutations in the coding regions of CFTR; in these patients, mutations within regulatory sequences of gene expression may be responsible of CF. A systematic study of CFTR introns is limited by the large number of sequences. Thus, we focused on intronic conserved sequence tag (CST), regions with a higher degree of homology between mouse and humans, that are the result of selective evolutionary pressure. CSTs provide a vast library of putative novel functional sites, such as nonpreviously described exon and/or elements possibly playing a role in regulating the gene expression, which may be functionally tested as well as screened for mutation in patients, particularly in disease where the molecular analysis of the coding regions failed in identifying a relevant number of causative mutations. In CFTR were found 52 CSTs in non-coding regions. Methods: All CFTR intronic CSTs were analyzed by gene scanning in 25 CF patients bearing one or both undetected mutations, 45 CF patients with a known genotype and 38 non-CF. Conclusion: The 57.6% of the regions did not show changes, while in 42.3% of the regions were observed 41 variants, including 16 novel. Furthermore, we selected 2 novel allelic variants for expression studies by the genetic reporter system in different cellular systems expressing and not expressing CFTR. In various cell lines, the first one showed a reduced transcriptional activity of the mutated construct in comparison to wild type; while the other one showed a increase of activity of the mutated form. CFTR is stimulated when cyclic AMP levels near the plasma membrane increase enough for protein kinase A (PKA) to be activated, triggering phosphorylation and channel opening. However, the family of exchange proteins directly activated by cyclic AMP (Epacs) also responds to direct binding of cAMP. Epacs are guanine nucleotide exchange factors for Rap GTPases, which are involved in cell-cell adhesion, cytoskeleton rearrangement and cell polarization, processes dysregulated in cystic fibrosis. Moreover, Epacs localize to the plasma membrane by scaffolding proteins that bind CFTR and PKA, namely ezrin-radixin-moesin (ERM) proteins. This suggests that activation of both CFTR and Epac might be spatially and temporally coincident. However, little is known concerning the involvement of Epacs in CFTR biology. Our aim was thus to elucidate the impact of Epacs in CFTR biogenesis and trafficking.
Here, we show that both Epacs and their effector Rap1 are expressed in A549 cells expressing CFTR under a Tet-ON promoter, CFBE lung epithelial cell lines and primary cultures of human bronchial epithelial cells. We also show by coimmunoprecipitation that Epac physically interacts with CFTR in A549 cells, supporting a functional interaction between the two proteins. Lastly, preliminary data suggest a decrease in CFTR steady-state levels when A549 cells are treated with a membrane-permeable Epac-selective cyclic AMP analogue that does not activate PKA. Taken together, our data support the hypothesis that Epacs may have a negative impact on CFTR membrane traffic. Work supported by CFF (USA) 7207534 grant, PTDC/BIA-BCM/112635/2009 and BioFig (PEst-OE/BIA/UI4046/2011) grants from FCT.
